Accord Healthcare launches Herceptin biosimilar in the UK
Zercepac will be available for HER2-positive breast and gastric cancers
Read More
Tag: HER2
US nod for Roche’s breast cancer combo
The therapy marks Roche’s first combination of two monoclonal antibodies administered in a single subcutaneous injection
Read More
NICE backs Roche’s Kadcyla for HER2-positive early breast cancer
Around 800 people will be eligible for treatment with Kadcyla
Read More
AZ, Daiichi HER-2 drug shows promise in mid-stage trial
Approximately one in five breast cancers are HER2-positive, meaning there is an unmet need for treatments.
Read More
Roche launches HER2 biomarker test for breast and gastric cancer
The test “advances Roche’s commitment to personalised healthcare”.
Read More
IGEM gets further funding for cancer drugs
The £750,000 grant will go to developing novel IgE antibodies, targeting HER2.
Read More
Roche’s Kadcyla shows promise in early breast cancer
Roche has announced that its antibody drug conjugate Kadcyla cut the risk of disease recurrence when given after neoadjuvant treatment and surgery to certain breast cancer patients with residual disease.
Read More
Daiichi to test cancer drug combo
Daiichi Sankyo has entered into a clinical trial collaboration agreement with a subsidiary of MSD to evaluate a potential new combination therapy for breast or lung cancers.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
